Disease Biology

1:27
Progress in AML & research at the University of Düsseldorf
Thomas Schröder
2:15
Transcription factor alterations in AML and risk: RUNX, CEPBA & EVI1
Ruud Delwel
2:06
EVI1 alteration in AML: mechanisms, disease risk & potential targeting
Ruud Delwel
1:25
Hellstrand lab leukemia research: exploring immune escape and defining therapeutic targets
Kristoffer Hellstrand
2:41
CAR-T19: A novel model of recognition
Jürgen Kuball
2:10
Single cell sequencing of AML: elucidating clonal heterogeneity
Klaus Metzeler
2:50
Investigating relapse after allo-SCT in AML
John DiPersio
4:23
Acute leukemias: the doubled-edged sword of genetic complexity
Tariq Mughal
3:21
NOX2: a potential immune checkpoint for inhibition in AML
Anna Martner
2:25
The importance of genetic profiling: NGS, MRD & beyond
Tariq Mughal
4:15
Precision medicine in hematological oncology: development to the present day
Tariq Mughal
3:03
Clonal interference of signaling mutations in AML: impacts on outcome
Raphael Itzykson
3:02
MRD monitoring by NGS in AML over time: revealing predictors of relapse
Peter Valk
2:45
Epigenetic alleles: an emerging concept
Ari Melnick
1:11
Jaiswal lab research and updates: mutations and age-related disease
Siddhartha Jaiswal
3:26
Clonal hematopoiesis of indeterminate potential (CHIP): genes, disease predisposition & potential
Siddhartha Jaiswal
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals